Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT5906 versus Lucentis in macular edema secondary to central retinal vein occlusion
CTR20253104Phase 3Active
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Sep 2025
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of BAT5906, ranibizumab in Vein occlusion (RVO), macular edema, sponsored by Bio-Thera Solutions, Ltd.. Started Sep 2025; status: active.
02
Drugs
BAT5906ranibizumab
03
Conditions
Vein occlusion (RVO)macular edema
Beyond the preview
Go deeper on CTR20253104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253104.